Patents by Inventor Daniel J. Kumke

Daniel J. Kumke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for preparing N-alkylated hydroxypyrimidinone compounds
    Patent number: 8357798
    Abstract: Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: January 22, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin M. Belyk, Henry G. Morrison, Philip Jones, Vincenzo Summa, V. Brett Cooper, Amar J. Mahajan, Daniel J. Kumke, Hsien-Hsin Tung, Lawrence Wai, Vanessa Pruzinsky, Philip Pye, Remy Angelaud, Danny Mancheno
  • Process for the production of a crystalline glucagon receptor antagonist compound
    Patent number: 8232413
    Abstract: The present invention relates to a process for the production of crystalline particles of a glucagon receptor antagonist compound. The process includes the steps of generating microseeds and subjecting the microseeds to a crystallization process. The resulting crystalline particles have a mean particle size of less than about 100 mm. The present invention also provides for a pharmaceutical composition which includes the crystalline particles produced by the method described herein and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: July 31, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Benjamin M. Cohen, Daniel J. Kumke, Lushi Tan, Aaron S. Cote
  • Polymorphic forms of a GABAA agonist
    Patent number: 8193216
    Abstract: The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: June 5, 2012
    Assignee: H. Lundbeck A/S
    Inventors: Daniel J. Kumke, Jerry A. Murry, Bryon L. Simmons, Feng Xu
  • POLYMORPHIC FORMS OF A GABAA AGONIST
    Publication number: 20110301190
    Abstract: The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.
    Type: Application
    Filed: August 16, 2011
    Publication date: December 8, 2011
    Applicant: H. LUNDBECK A/S
    Inventors: Daniel J. Kumke, Jerry A. Murry, Bryon L. Simmons, Feng Xu
  • Polymorphic forms of a GABAagonist
    Patent number: 8022084
    Abstract: The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.
    Type: Grant
    Filed: January 26, 2006
    Date of Patent: September 20, 2011
    Assignee: H. Lundbeck A/S
    Inventors: Daniel J. Kumke, Jerry A. Murry, Bryon L. Simmons, Feng Xu
  • PROCESS FOR THE PRODUCTION OF A CRYSTALLINE GLUCAGON RECEPTOR ANTAGONIST COMPOUND
    Publication number: 20100184995
    Abstract: The present invention relates to a process for the production of crystalline particles of a glucagon receptor antagonist compound. The process includes the steps of generating microseeds and subjecting the microseeds to a crystallization process. The resulting crystalline particles have a mean particle size of less than about 100 mm. The present invention also provides for a pharmaceutical composition which includes the crystalline particles produced by the method described herein and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 8, 2008
    Publication date: July 22, 2010
    Inventors: Benjamin M. Cohen, Daniel J. Kumke, Lushi Tan, Aaron S. Cote
  • Potassium salt of an HIV integrase inhibitor
    Patent number: 7754731
    Abstract: Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: July 13, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin M. Belyk, Henry G. Morrison, Amar J. Mahajan, Daniel J. Kumke, Hsien-Hsin Tung, Lawrence Wai, Vanessa Pruzinsky